<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114382">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002767</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-281-1056</org_study_id>
    <secondary_id>2013-004113-41</secondary_id>
    <nct_id>NCT02002767</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>New Zealand: Standing Committee on Therapeutic Trials - (SCOTT)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the single-dose pharmacokinetics (PK), safety, and tolerability of
      GS-5816 in participants with severe renal impairment using matched healthy participants as a
      control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters of GS-5816 as measured by AUClast, AUCinf, and Cmax</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration
AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time)
Cmax is defined as the maximum concentration of drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to Day 6 plus 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence of adverse events will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of vital signs</measure>
    <time_frame>Baseline to Day 6 plus 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Information on vital signs, including electrocardiograms (ECGs), will be collected and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Baseline to Day 6 plus 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence of laboratory abnormalities will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Participants with renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment will receive a single dose of GS-5816.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with normal renal function will receive a single dose of GS-5816.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5816</intervention_name>
    <description>GS-5816 100 mg (2 x 50 mg tablets) administered orally</description>
    <arm_group_label>Participants with renal impairment</arm_group_label>
    <arm_group_label>Participants with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General good health with stable chronic kidney disease in Severe Renal Impairment
             Group

          -  Screening labs within defined thresholds

          -  Creatinine clearance must be &lt; 30 mL/min for Severe Renal Impairment group, and â‰¥ 90
             mL/min for  Normal Renal Function group

        Exclusion Criteria:

          -  Females who are pregnant or nursing, or males who have a pregnant partner

          -  Infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV

          -  History of clinically significant illness (including psychiatric or cardiac) or any
             other medical disorder that may interfere with subject treatment and/or adherence to
             the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa Stamm, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>Karim.Sajwani@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>08011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
